JP2016530323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530323A5 JP2016530323A5 JP2016542315A JP2016542315A JP2016530323A5 JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- tumor
- antigen
- administered
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 229950009791 durvalumab Drugs 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 12
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 5
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 3
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 230000002055 immunohistochemical effect Effects 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 86
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- -1 bevacizumab Chemical compound 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876509P | 2013-09-11 | 2013-09-11 | |
| US61/876,509 | 2013-09-11 | ||
| US201461971212P | 2014-03-27 | 2014-03-27 | |
| US61/971,212 | 2014-03-27 | ||
| US201461978401P | 2014-04-11 | 2014-04-11 | |
| US61/978,401 | 2014-04-11 | ||
| US201462003349P | 2014-05-27 | 2014-05-27 | |
| US62/003,349 | 2014-05-27 | ||
| PCT/EP2014/069425 WO2015036499A1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Division JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530323A JP2016530323A (ja) | 2016-09-29 |
| JP2016530323A5 true JP2016530323A5 (enExample) | 2017-10-12 |
| JP6550053B2 JP6550053B2 (ja) | 2019-07-24 |
Family
ID=51570487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542315A Active JP6550053B2 (ja) | 2013-09-11 | 2014-09-11 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10336823B2 (enExample) |
| EP (2) | EP3043816B1 (enExample) |
| JP (5) | JP6550053B2 (enExample) |
| KR (4) | KR20240056664A (enExample) |
| CN (2) | CN105873606B (enExample) |
| AU (3) | AU2014320343B2 (enExample) |
| BR (1) | BR112016005303A2 (enExample) |
| CA (1) | CA2923499A1 (enExample) |
| DK (1) | DK3043816T3 (enExample) |
| ES (1) | ES2749744T3 (enExample) |
| HU (1) | HUE046674T2 (enExample) |
| IL (5) | IL313188B1 (enExample) |
| MX (1) | MX370818B (enExample) |
| NZ (2) | NZ757060A (enExample) |
| PL (1) | PL3043816T3 (enExample) |
| RU (1) | RU2701327C2 (enExample) |
| SA (1) | SA516370713B1 (enExample) |
| TW (1) | TWI643633B (enExample) |
| WO (1) | WO2015036499A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102389677B1 (ko) | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| IL313188B1 (en) * | 2013-09-11 | 2025-08-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR20240110004A (ko) | 2014-03-14 | 2024-07-12 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2015181342A1 (en) | 2014-05-29 | 2015-12-03 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| CN106456764A (zh) * | 2014-05-29 | 2017-02-22 | 免疫医疗有限公司 | 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| EP3189080A1 (en) * | 2014-09-05 | 2017-07-12 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| CN107530434A (zh) * | 2015-04-23 | 2018-01-02 | 免疫医疗有限公司 | 非小细胞肺癌egfr突变阳性的联合疗法 |
| CN107667119A (zh) * | 2015-05-12 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| MX390878B (es) | 2015-06-16 | 2025-03-21 | Merck Patent Gmbh | Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1). |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| EP3464356A1 (en) * | 2016-05-26 | 2019-04-10 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for cancer treatment |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018003995A1 (ja) * | 2016-07-01 | 2018-01-04 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN111372934B (zh) | 2017-08-18 | 2024-04-26 | 科瑞华生物技术有限公司 | Tg02的多晶型形式 |
| WO2019152743A1 (en) * | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| CN119899267A (zh) * | 2018-03-22 | 2025-04-29 | 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 | 拮抗性pd-1、pd-l1和lag-3结合蛋白 |
| CN113438947A (zh) | 2019-01-18 | 2021-09-24 | 羿尊生物医药股份有限公司 | Don前药和免疫检查点抑制剂的联合治疗 |
| WO2020151759A1 (zh) * | 2019-01-25 | 2020-07-30 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| MX2021011753A (es) | 2019-03-26 | 2022-01-31 | Univ Michigan Regents | Degradadores de moleculas peque?as de stat3. |
| EP3947403A1 (en) | 2019-03-29 | 2022-02-09 | The Regents Of The University Of Michigan | Stat3 protein degraders |
| AU2020291936A1 (en) | 2019-06-12 | 2022-02-03 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| AU2020291464A1 (en) | 2019-06-12 | 2022-02-03 | Vanderbilt University | Amino acid transport inhibitors and the uses thereof |
| AU2020301417A1 (en) * | 2019-06-25 | 2022-01-06 | City Of Hope | PDL1 positive NK cell cancer treatment |
| CN115443329A (zh) | 2019-06-27 | 2022-12-06 | 乔治华盛顿大学国会特许非营利公司 | Hdac6激活的巨噬细胞、其组合物及用途 |
| PH12021553233A1 (en) | 2019-07-16 | 2022-09-19 | Univ Michigan Regents | Imidazopyrimidines as eed inhibitors and the use thereof |
| CN114641337A (zh) | 2019-08-27 | 2022-06-17 | 密歇根大学董事会 | Cereblon e3连接酶抑制剂 |
| EP4031241A1 (en) | 2019-09-19 | 2022-07-27 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
| JP7445752B2 (ja) * | 2019-09-25 | 2024-03-07 | ウーシー バイオロジクス アイルランド リミテッド | 新規の抗ｐｄ－ｌ１抗体 |
| US20230159573A1 (en) | 2020-03-26 | 2023-05-25 | The Regents Of The University Of Michigan | Small molecule stat protein degraders |
| WO2022011204A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| US20230233690A1 (en) | 2020-07-10 | 2023-07-27 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| WO2022072820A1 (en) | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| WO2022187419A1 (en) | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| US20240166647A1 (en) | 2021-03-03 | 2024-05-23 | The Regents Of The University Of Michigan | Cereblon Ligands |
| WO2022200557A1 (en) * | 2021-03-26 | 2022-09-29 | Astrazeneca Ab | Combination treatments for melanoma |
| TW202444754A (zh) | 2023-01-30 | 2024-11-16 | 英商凱麥博有限公司 | 抗體 |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| WO2002086083A2 (en) * | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN101693562A (zh) * | 2009-10-21 | 2010-04-14 | 山东大学 | 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂 |
| DK2504364T3 (da) * | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| SMT202000561T1 (it) * | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| SG10201700698WA (en) * | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| IL313188B1 (en) | 2013-09-11 | 2025-08-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| MX373019B (es) * | 2014-05-13 | 2020-03-31 | Medimmune Ltd | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4). |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3189080A1 (en) * | 2014-09-05 | 2017-07-12 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
| EP3220951A1 (en) * | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| SG11201807474SA (en) * | 2016-04-25 | 2018-11-29 | Medimmune Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| AU2017264944A1 (en) * | 2016-05-13 | 2018-12-20 | Medimmune, Llc | CD40L-Fc fusion polypeptides and methods of use thereof |
-
2014
- 2014-09-11 IL IL313188A patent/IL313188B1/en unknown
- 2014-09-11 ES ES14766962T patent/ES2749744T3/es active Active
- 2014-09-11 CA CA2923499A patent/CA2923499A1/en active Pending
- 2014-09-11 RU RU2016113341A patent/RU2701327C2/ru active
- 2014-09-11 KR KR1020247013414A patent/KR20240056664A/ko not_active Ceased
- 2014-09-11 CN CN201480049982.1A patent/CN105873606B/zh active Active
- 2014-09-11 TW TW103131437A patent/TWI643633B/zh active
- 2014-09-11 MX MX2016002826A patent/MX370818B/es active IP Right Grant
- 2014-09-11 CN CN202011433007.4A patent/CN112546217B/zh active Active
- 2014-09-11 KR KR1020167007277A patent/KR102329584B1/ko active Active
- 2014-09-11 KR KR1020227040760A patent/KR102661249B1/ko active Active
- 2014-09-11 EP EP14766962.6A patent/EP3043816B1/en active Active
- 2014-09-11 PL PL14766962T patent/PL3043816T3/pl unknown
- 2014-09-11 HU HUE14766962A patent/HUE046674T2/hu unknown
- 2014-09-11 NZ NZ757060A patent/NZ757060A/en unknown
- 2014-09-11 IL IL292193A patent/IL292193B2/en unknown
- 2014-09-11 JP JP2016542315A patent/JP6550053B2/ja active Active
- 2014-09-11 IL IL321966A patent/IL321966A/en unknown
- 2014-09-11 DK DK14766962.6T patent/DK3043816T3/da active
- 2014-09-11 BR BR112016005303A patent/BR112016005303A2/pt not_active Application Discontinuation
- 2014-09-11 KR KR1020217037457A patent/KR20210143932A/ko not_active Ceased
- 2014-09-11 NZ NZ718821A patent/NZ718821A/en unknown
- 2014-09-11 EP EP19191552.9A patent/EP3656398A1/en active Pending
- 2014-09-11 AU AU2014320343A patent/AU2014320343B2/en active Active
- 2014-09-11 WO PCT/EP2014/069425 patent/WO2015036499A1/en not_active Ceased
- 2014-09-11 US US15/021,161 patent/US10336823B2/en active Active
-
2016
- 2016-03-03 IL IL244422A patent/IL244422B/en active IP Right Grant
- 2016-03-10 SA SA516370713A patent/SA516370713B1/ar unknown
-
2019
- 2019-04-23 JP JP2019081639A patent/JP2019163269A/ja active Pending
- 2019-05-21 US US16/418,488 patent/US10829557B2/en active Active
-
2020
- 2020-05-05 IL IL274462A patent/IL274462B/en unknown
- 2020-08-27 AU AU2020223728A patent/AU2020223728B2/en active Active
- 2020-09-10 JP JP2020152079A patent/JP7119037B2/ja active Active
- 2020-10-16 US US17/072,756 patent/US11827706B2/en active Active
-
2022
- 2022-02-16 JP JP2022021883A patent/JP7342167B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139429A patent/JP2023166474A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203898A patent/AU2024203898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530323A5 (enExample) | ||
| RU2016113341A (ru) | Антитела к b7-h1 для лечения опухолей | |
| JP2016520082A5 (enExample) | ||
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| JP2017537090A5 (enExample) | ||
| JP2018512391A5 (enExample) | ||
| Chami et al. | Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma | |
| JP2008500964A5 (enExample) | ||
| US9415078B2 (en) | Method of treating desmocollin-3 expressing cancer with Mycobacterium w | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP2018501247A5 (enExample) | ||
| JPWO2020223702A5 (enExample) | ||
| Besse et al. | Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) | |
| RU2812782C2 (ru) | Способ лечения острого миелоидного лейкоза | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| RU2023133857A (ru) | Антитела к b7-h1 для лечения опухолей | |
| JPWO2020150434A5 (enExample) | ||
| Henry et al. | 325 MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation | |
| WO2023185720A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| CN120605267A (zh) | 双氢青蒿素在制备结直肠癌转移药物方面的应用 | |
| CN119212695A (zh) | 施用用于诱导肿瘤相关抗原的苔藓虫素的方法 | |
| Ciprotti et al. | 323 A Pilot Study of the Safety, Efficacy and Effects On Functional Imaging of the Combination of CG250 and Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) | |
| Grifantini et al. | 324 Monoclonal Antibodies Against Novel Tumor Markers for Diagnostic Prognostic and Predictive Applications | |
| RU2019129614A (ru) | Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого |